Literature DB >> 13806299

Prognosis of the eczema-asthma syndrome.

D BURROWS, R W PENMAN.   

Abstract

Entities:  

Keywords:  ECZEMA/in infancy and childhood

Mesh:

Year:  1960        PMID: 13806299      PMCID: PMC2097805          DOI: 10.1136/bmj.2.5202.825

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  7 in total

1.  Infantile eczema: observations on natural history and prognosis.

Authors:  M VOWLES; R P WARIN; J APLEY
Journal:  Br J Dermatol       Date:  1955-02       Impact factor: 9.302

2.  Respiratory studies in children. VI. Timed vital capacity in healthy children and in symptom-free asthmatic children.

Authors:  I ENGSTROM; F E ESCARDO; P KARLBERG; S KRAEPELIEN
Journal:  Acta Paediatr       Date:  1959-03       Impact factor: 2.299

3.  Pulmonary function studies in normal boys.

Authors:  M C KENNEDY; D C THURSBY-PELHAM; P D OLDHAM
Journal:  Arch Dis Child       Date:  1957-08       Impact factor: 3.791

4.  [Phenotypical familial pathological reactions of atopic disorders (constitutional neurodermatitis, bronchial asthma, rhinitis allergica)].

Authors:  U W SCHNYDER; W KLUNKER
Journal:  Hautarzt       Date:  1957-11       Impact factor: 0.751

5.  Infantile eczema.

Authors:  J T INGRAM
Journal:  Aust J Dermatol       Date:  1955-07

6.  The long-term prognosis in infantile eczema.

Authors:  M J PURDY
Journal:  Br Med J       Date:  1953-06-20

7.  Air velocity index; a numerical expression of the functionally effective portion of ventilation.

Authors:  E A GAENSLER
Journal:  Am Rev Tuberc       Date:  1950-07
  7 in total
  2 in total

1.  [The treatment of atopic dermatitis in adults with topical calcineurin inhibitors].

Authors:  M Meurer; G Wozel
Journal:  Hautarzt       Date:  2003-04-04       Impact factor: 0.751

Review 2.  Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice.

Authors:  Raj Chovatiya; Jonathan I Silverberg
Journal:  Am J Clin Dermatol       Date:  2022-05-31       Impact factor: 6.233

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.